VistaGen Therapeutics, Inc. - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by VistaGen Therapeutics, Inc. on January 15, 2019, covering events that occurred on January 10, 2019. The filing primarily addresses corporate governance changes regarding the Board of Directors.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on the appointment of a new director and does not contain financial performance data.
Material Changes
- Board Appointment: Ann Cunningham, M.B.A., was appointed to the Board of Directors and designated as an independent director.
- Committee Assignment: Ms. Cunningham was appointed to the Corporate Governance and Nominating Committee.
- Indemnification: The Company entered into an Indemnification Agreement with Ms. Cunningham, requiring the Company to indemnify her to the fullest extent permitted under Nevada law and advance certain legal expenses.
Guidance, Outlook, and Risks
The filing does not contain financial guidance, outlook, or management commentary regarding business operations. No specific risks or contingencies related to financial performance were disclosed in this document. The text confirms there are no undisclosed arrangements or related party transactions involving Ms. Cunningham.
Key Facts for Investor Verification
- Verify the independence status of Ann Cunningham under Nasdaq listing rules.
- Review the full text of the Indemnification Agreement (Exhibit 10.1) for specific liability terms.
- Confirm the press release details (Exhibit 99.1) for any additional context on the appointment.
- Note that this filing contains no financial data; refer to the most recent 10-K or 10-Q for financial metrics.